Home/Pipeline/Platform-derived Immunotherapy

Platform-derived Immunotherapy

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

GenCirq

About GenCirq

GenCirq is a private, preclinical-stage biotech based in San Diego, pioneering a novel approach to cancer therapy using engineered bacteria. The company's platform is built on foundational research from leading institutions, utilizing bacteria's natural tumor-homing ability to deliver a range of therapeutics, such as immunostimulatory agents, directly into the tumor microenvironment via a genetically programmed lysis mechanism. This approach aims to enhance efficacy and safety by localizing treatment and minimizing systemic exposure. GenCirq is positioned to address significant unmet needs in solid tumor oncology with a potentially versatile and cost-effective therapeutic delivery system.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active